StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly cOVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy] (%)

Quarterly figures from Eli Lilly's filings and investor materials

Latest, Q4 2023
-100.0%
Period ended Dec 31, 2023
Change on a year earlier
-4.0 pts
-96.0% in Q4 2022
History
9 quarters
Since Q4 2021
Sources
9
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCOVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy] (%)Year on yearSource
Q4 2023Dec 31, 2023-100.0%-4.0 ptsEarnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
Q3 2023Sep 30, 2023-100.0%-178.0 ptsForm 10-Q FY2023Q3 (filed 2023-11-02) ↗
Q2 2023Jun 30, 2023-100.0%-87.0 ptsForm 10-Q FY2023Q2 (filed 2023-08-08) ↗
Q1 2023Mar 31, 2023-100.0%-181.0 ptsForm 10-Q FY2023Q1 (filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-96.0%-118.0 ptsEarnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗
Q3 2022Sep 30, 202278.0%–Form 10-Q FY2022Q3 (filed 2022-11-01) ↗
Q2 2022Jun 30, 2022-13.0%–Form 10-Q FY2022Q2 (filed 2022-08-04) ↗
Q1 2022Mar 31, 202281.0%–Form 10-Q FY2022Q1 (filed 2022-04-29) ↗
Q4 2021Dec 31, 202122.0%–Earnings Release (Form 8-K FY2021Q4 EX-99.1) (filed 2022-02-03) ↗

Cite this data

StockData. (2026). Eli Lilly COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy] (%), quarterly Q4 2021–Q4 2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_covid19antibodies_yoy

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.